Navigation Links
YM BIOSCIENCES ANNOUNCES NIMOTUZUMAB PRESENTATIONS TO BE MADE AT THE 100TH ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH AND EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY
Date:3/13/2009

ter Capital Management, LLC and associated companies decreased holdings in the Company to 2,814,932 common shares, representing 4.8 per cent voting rights attached to the issued common share capital of the Company, being 58,216,309 common shares. This information is being provided in order to comply with the rules for AIM listed companies.

About YM BioSciences

YM BioSciences Inc. is a life sciences product development company that identifies and advances a diverse portfolio of promising cancer-related products at various stages of development. The Company is currently developing two late-stage products: nimotuzumab, an EGFR-targeting Affinity-Optimized Antibody(TM), and AeroLEF(R), a proprietary, inhaled-delivery composition of free and liposome-encapsulated fentanyl. YM has proven regulatory and clinical trial expertise and a diversified business model designed to reduce risk while advancing clinical products toward international approval, marketing and commercialization.

Nimotuzumab is a humanized monoclonal antibody in development worldwide, targeting multiple tumor types primarily in combination with radiation and chemoradiation. It is significantly differentiated from all other currently marketed EGFR-targeting agents due to its remarkably benign side-effect profile. Nimotuzumab's anti-tumor activity has led to its approval for marketing in over 12 countries, In more than 3,500 patients reported as having been treated with nimotuzumab worldwide to date, no Grade IV incidents of radiation dermatitis have been described, severe rash has not been observed and reports of the other severe side-effects that are typical of EGFR-targeting molecules have been rare. Nimotuzumab is licensed to YM's majority-owned subsidiary, CIMYM BioSciences Inc., by CIMAB S.A., and was developed at the Center of Molecular Immunology. YM is developing AeroLEF for the treatment of moderate to severe acute pain. The product is differentiated from o
'/>"/>

SOURCE YM BioSciences Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Sangamo BioSciences Announces Presentations at Two Upcoming Investor Conferences
2. Hana Biosciences Announces New Positive Interim Efficacy Results in Pivotal rALLy Clinical Trial of Marqibo in Acute Lymphoblastic Leukemia
3. Hana Biosciences Announces Successful Planned Independent Safety Analysis Supports Ability to Complete Pivotal rALLy Clinical Trial of Marqibo, Its Lead Novel Anti-Cancer Compound
4. Cardio3 BioSciences Raises EUR13.7 Million in Series B Fundraising and Grant Funding
5. YM BioSciences Announces Milestone Payment For Approval Of Nimotuzumab In The Philippines And Indonesia
6. Sangamo BioSciences Provides Update on Companys 2008 Progress and 2009 Objectives
7. Chipscreen Biosciences and HUYA Bioscience Intl Announce Promising Preclincial and Phase I Solid Tumor/Lymphoma Data for Chidamide/HBI-8000, New HDAC Inhibitor for Cancer
8. Regado Biosciences Completes Patient Enrollment for Phase IIa Study of REG1 Anticoagulation System
9. Ardea Biosciences Presents Preclinical Anti-Inflammatory Data on its Lead MEK Inhibitor, RDEA119, at the ACG 2008 Annual Meeting
10. Epiphany Biosciences to Continue Phase 2 Shingles Study After Interim Analysis; Plans Follow-On Clinical Trial Studying Post-Herpetic Neuralgia (PHN)
11. Ardea Biosciences to Present Data on Lead MEK Inhibitor, RDEA119, at American College of Gastroenterology Annual Scientific Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/14/2014)... 2014  Invivotek L.L.C., a member of the ... that its animal research facility was awarded full ... Accreditation of Laboratory Animal Care International (AAALAC). AAALAC ... worldwide through voluntary accreditation and assessment programs. AAALAC ... use in 38 countries. Invivotek was ...
(Date:7/14/2014)... 14, 2014 Valeant Pharmaceuticals International, Inc. ... today announced it has filed a premerger notification ... (HSR) with the U.S. Federal Trade Commission (FTC) ... (NYSE: AGN). About Valeant Pharmaceuticals ... Inc. (NYSE/TSX: VRX) is a multinational specialty pharmaceutical ...
(Date:7/14/2014)... , July 14, 2014  Mallinckrodt plc (NYSE: ... QCOR ) today announced that the registration statement on Form ... by Mallinckrodt plc on May 16, 2014 and amended on ... Mallinckrodt and Questcor that also constitutes a prospectus of Mallinckrodt, ... on Form S-4 is available on the SEC,s EDGAR system, ...
Breaking Medicine Technology:Invivotek Awarded Full AAALAC Accreditation for Excellence in Laboratory Animal Care and Use 2Valeant Pharmaceuticals Submits HSR Filing Relating To Proposed Acquisition Of Allergan 2Valeant Pharmaceuticals Submits HSR Filing Relating To Proposed Acquisition Of Allergan 3Valeant Pharmaceuticals Submits HSR Filing Relating To Proposed Acquisition Of Allergan 4Valeant Pharmaceuticals Submits HSR Filing Relating To Proposed Acquisition Of Allergan 5Mallinckrodt Pharmaceuticals And Questcor Pharmaceuticals Provide Update On Transaction 2Mallinckrodt Pharmaceuticals And Questcor Pharmaceuticals Provide Update On Transaction 3Mallinckrodt Pharmaceuticals And Questcor Pharmaceuticals Provide Update On Transaction 4Mallinckrodt Pharmaceuticals And Questcor Pharmaceuticals Provide Update On Transaction 5Mallinckrodt Pharmaceuticals And Questcor Pharmaceuticals Provide Update On Transaction 6Mallinckrodt Pharmaceuticals And Questcor Pharmaceuticals Provide Update On Transaction 7
... WASHINGTON, Sept. 19 The Richard B. and ... Birch McCormick,Genomics Center at The George Washington ... the issues and implications around the growing ... This symposium is,intended to provide a valuable ...
... Mich., Sept. 19 A new topical lotion ... eliminate serious skin,infections, but without being systemically absorbed, ... in patients with onychomycosis, or,toenail fungus, a new ... 1 clinical trial are important to the fields ...
Cached Medicine Technology:Personalized Medicine - The Genomic Revolution in Cardiac Care 2Personalized Medicine - The Genomic Revolution in Cardiac Care 3New Topical Therapy Safely Treats Serious Skin Infections Without Systemic Side Effects 2New Topical Therapy Safely Treats Serious Skin Infections Without Systemic Side Effects 3
(Date:7/14/2014)... Last month Bromell Agency officially launched the ... features more detailed information on how clients can protect ... and boats in the state of Louisiana. , The ... the website in order to better educate clients on ... of the website, which is to display comprehensive insurance ...
(Date:7/14/2014)... Academy, senescent is he who "begins to age". But ... is senescence not a synonym of ageing, it is ... is such a badly named physiological process that those ... another name. That is the case of Manuel Serrano, ... of the world,s leading experts on senescence, who has ...
(Date:7/14/2014)... 2014 Physical fitness may buffer some of the adverse ... new study by researchers from the American Cancer Society, ... study appears in the journal Mayo Clinic Proceeding ... and obesity and blood markers associated with cardiovascular disease ... , Sedentary behavior has been linked to an increase ...
(Date:7/14/2014)... Botanica Day Spa announced last month that their ... the day spa in down town Clearwater, FL on ... refreshments will be served as clients are invited to ... and great deals on spa services, including the ... (also known as “facial shaving”) is a simple and ...
(Date:7/14/2014)... -- Being physically active in middle age appears to ... types of dementia, suggest the findings from two new ... exercise at various levels, especially in midlife, is beneficial ... Clinic, said in an Alzheimer,s Association news release. ... conclusive. More research is needed to determine the extent ...
Breaking Medicine News(10 mins):Health News:Manuel Serrano proposes a new vision of a process wrongly associated with ageing 2Health News:Manuel Serrano proposes a new vision of a process wrongly associated with ageing 3Health News:Physical fitness associated with less pronounced effect of sedentary behavior 2Health News:Botanica Day Spa to Feature Dermaplaning at Upcoming Open House 2Health News:Botanica Day Spa to Feature Dermaplaning at Upcoming Open House 3Health News:Staying Active May Help Prevent Dementia 2
... Food and Drug Administration,s (FDA) recent decision to approve ... treatment of non-Hodgkin,s lymphoma (NHL). "This is ... M. Graham, M.D., Ph.D., president of SNM and director ... College of Medicine. "We,ve known for some time that ...
... , ... superstore has beaten the thirty cents per card - three day production threshold on quantities ... Fort ... so few plastic cards so fast and at this price level. This is a special ...
... , , Members Take to ... with Constituent Health Care Stories to Congress , ... health care reform speech, and with Congress back to work in Washington, AARP ... what,s broken and preserve what,s right. , , ...
... , BELGRADE, Serbia, Sept. 10 /PRNewswire-FirstCall/ - HTDS ... its operating subsidiary Slavica Bio Chem www.slavicabiochem.com ... , , The equipment is ... http://www.expressionproteomics.com/LifeScience/pdf/Bulletin_3095.pdf , , , Dr.Ivana Gadjanski HTDS ...
... TEANECK, N.J., Sept. 10 After an 8 day trial, ... on September 4, 2009 by the Superior Court of New Jersey ... breaching her duty of loyalty. , , ... 2009, Ellen Koblitz, Presiding Judge of the Superior Court of New ...
... WALTHAM, Mass., Sept. 10 Inverness Medical Innovations, Inc. (NYSE: ... take charge of their health at home through the merger of ... several healthcare industry investor conferences during the month of September. , ... Chief Executive Officer, and Jon Russell, Vice President, Finance, will attend ...
Cached Medicine News:Health News:SNM applauds FDA's decision to approve Zevalin 2Health News:My1Stop.com Offers Plastic Card Printing Promotion Beats the Thirty Cents per Card Threshold - Offering 1000 Cards in Only Three Days for $299 2Health News:AARP Delivers Health Care Reform 'Message in a Bottle' in Chicago 2Health News:Hard To Treat Diseases (HTDS) Equipment Purchase, and General Update on its Cancer and Anti Aging Projects 2Health News:Hard To Treat Diseases (HTDS) Equipment Purchase, and General Update on its Cancer and Anti Aging Projects 3Health News:Inverness Medical Innovations Announces September Investor Conference Schedule 2
... The VersaPulse® PowerSuite™ holmium laser ... properties for precise, virtually bloodless procedures. ... fragmenting urinary and gall bladder stones ... ideal multipurpose surgical tool. Because its ...
... The VersaPulse® PowerSuite™ holmium laser combines ... for precise, virtually bloodless procedures. It ... urinary and gall bladder stones of ... multipurpose surgical tool. Because its laser ...
Turnstile casting stand for easy and safe casting. The compact system sets up quickly and stores conveniently, and the non-stick coating prevents fiberglass or plaster from adhering to surface....
... Cemex features a unique self-contained ... clinically proven in Europe for ... integrating bone cement powder and ... system, Cemex is designed to ...
Medicine Products: